Update on the management of overactive bladder

1. Haylen, BT, de Ridder, D, Freeman, RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010; 21: 5–26.
Google Scholar | Crossref | Medline | ISI2. Milsom, I, Abrams, P, Cardozo, L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760–766.
Google Scholar | Crossref | Medline | ISI3. Coyne, KS, Margolis, MK, Kopp, ZS, et al. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. Urology 2012; 79: 95–101.
Google Scholar | Crossref | Medline | ISI4. Coyne, KS, Sexton, CC, Bell, JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn 2013; 32: 230–237.
Google Scholar | Crossref | Medline | ISI5. Hu, TW, Wagner, TH, Bentkover, JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003; 61: 1123–1128.
Google Scholar | Crossref | Medline | ISI6. American Urological Association . Overactive Bladder (OAB) guideline, https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline (2020, accessed 29 December 2020).
Google Scholar7. European Association of Urology . EAU Guidelines: urinary incontinence, https://uroweb.org/guideline/urinary-incontinence/ (2020, accessed 29 December 2020).
Google Scholar8. NICE Pathways . Managing overactive bladder in women, https://pathways.nice.org.uk/pathways/urinary-incontinence-and-pelvic-organ-prolapse-in-women/managing-overactive-bladder-in-women#content=view-node%3Anodes-augmentation-cystoplasty-for-idiopathic-detrusor-overactivity&path=view%3A/pathways/urinary-incontinence-and-pelvic-organ-prolapse-in-women/invasive-procedures-for-overactive-bladder-in-women.xml (2020, accessed 29 December 2020).
Google Scholar9. Truzzi, JC, Gomes, CM, Bezerra, CA, et al. Overactive bladder – 18 years – Part I. Int Braz J Urol 2016; 42: 188–198.
Google Scholar | Crossref | Medline10. Hashim, H, Abrams, P. Is the bladder a reliable witness for predicting detrusor overactivity?. J Urol 2006; 175: 191–194.
Google Scholar | Crossref | Medline | ISI11. NIHR Funding and Awards Search Website [Internet] . Fundingawards.nihr.ac.uk, https://www.fundingawards.nihr.ac.uk/award/15/150/05 (2021, accessed 23 January 2021).
Google Scholar12. Arnold, J, McLeod, N, Thani-Gasalam, R, et al. Overactive bladder syndrome: management and treatment options. Aust J Gen Pract 2012; 41: 878–883.
Google Scholar13. Markland, AD, Vaughan, CP, Johnson, TM, et al. Incontinence. Med Clin North Am 2011; 95: 539–554.
Google Scholar | Crossref | Medline14. Hashim, H, Abrams, P. How should patients with an overactive bladder manipulate their fluid intake?. BJU Int 2008; 102: 62–66.
Google Scholar | Crossref | Medline15. Swithinbank, L, Hashim, H, Abrams, P. The effect of fluid intake on urinary symptoms in women. J Urol 2005; 174: 187–189.
Google Scholar | Crossref | Medline | ISI16. Wells, MJ, Jamieson, K, Markham, TC, et al. The effect of caffeinated versus decaffeinated drinks on overactive bladder: a double-blind, randomized, crossover study. J Wound Ostomy Continence Nurs 2014; 41: 371–378.
Google Scholar | Crossref | Medline17. Srikrishna, S, Robinson, D, Cardozo, L, et al. Management of overactive bladder syndrome. Postgrad Med J 2007; 83: 481–486.
Google Scholar | Crossref | Medline18. Pelletier, EM, Vats, V, Clemens, JQ. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. Am J Manag Care 2009; 15(Suppl. 4): S108–S114.
Google Scholar | Medline19. Araklitis, G, Robinson, D, Cardozo, L. Cognitive effects of anticholinergic load in women with overactive bladder. Clin Interv Aging 2020; 15: 1493–1503.
Google Scholar | Crossref | Medline20. Lozano-Ortega, G, Johnston, KM, Cheung, A, et al. A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr 2020; 87: 103885.
Google Scholar | Crossref | Medline21. Wagg, A, Compion, G, Fahey, A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012; 110: 1767–1774.
Google Scholar | Crossref | Medline | ISI22. Epstein, BJ, Gums, JG, Molina, E. Newer agents for the management of overactive bladder. Am Fam Physician 2006; 74: 2061–2068.
Google Scholar | Medline | ISI23. Cui, Y, Zong, H, Yang, C, et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol 2014; 46: 275–284.
Google Scholar | Crossref | Medline | ISI24. Shamliyan, T, Wyman, J, Kane, RL. Nonsurgical treatments for urinary incontinence in adult women: diagnosis and comparative effectiveness. Comparative Effectiveness Reviews, No. 36. Rockville, MD: Agency for Healthcare Research and Quality, 2012.
Google Scholar25. Chapple, CR, Nazir, J, Hakimi, Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol 2017; 72: 389–399.
Google Scholar | Crossref | Medline | ISI26. Chapple, CR, Kaplan, SA, Mitcheson, D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β3-adrenoceptor agonist, in overactive bladder. Eur Urol 2013; 63: 296–305.
Google Scholar | Crossref | Medline | ISI27. Mirabegron (Betmiga▼): risk of severe hypertension and associated cerebrovascular and cardiac events [Internet] . GOV.UK., https://www.gov.uk/drug-safety-update/mirabegron-betmiga-risk-of-severe-hypertension-and-associated-cerebrovascular-and-cardiac-events (2021, accessed 23 January 2021).
Google Scholar28. Herschorn, S, Chapple, CR, Abrams, P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 2017; 120: 562–575.
Google Scholar | Crossref | Medline29. Drake, MJ, Chapple, C, Esen, AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol 2016; 70: 136–145.
Google Scholar | Crossref | Medline | ISI30. Abrams, P, Kelleher, C, Staskin, D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony). Eur Urol 2015; 67: 577–588.
Google Scholar | Crossref | Medline | ISI31. Yoshida, M, Takeda, M, Gotoh, M, et al. Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol 2018; 73: 783–790.
Google Scholar | Crossref | Medline32. Bientinesi, R, Sacco, E. Managing urinary incontinence in women – a review of new and emerging pharmacotherapy. Expert Opin Pharmacother 2018; 19: 1989–1997.
Google Scholar | Crossref | Medline33. Brubaker, L, Richter, HE, Visco, A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180: 217–222.
Google Scholar | Crossref | Medline | ISI34. Sahai, A, Khan, MS, Dasgupta, P; GKT Botulinum Study Group . Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177: 2231–2236.
Google Scholar | Crossref | Medline | ISI35. Siegel, S, Noblett, K, Mangel, J, et al. Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol 2018; 199: 229–236.
Google Scholar | Crossref | Medline36. van Kerrebroeck, PE, van Voskuilen, AC, Heesakkers, JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007; 178: 2029–2034.
Google Scholar | Crossref | Medline | ISI37. Gandhi, S, Gajewski, JB, Koziarz, A, et al. Long-term outcomes of sacral neuromodulation for lower urinary tract dysfunction: a 23-year experience. Neurourol Urodyn 2021; 40: 461–469.
Google Scholar | Crossref | Medline38. Amundsen, CL, Komesu, YM, Chermansky, C, et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol 2018; 74: 66–73.
Google Scholar | Crossref | Medline39. Ghoniem, G . Use of new rechargeable battery and MRI-Friendly technologies in sacral neuromodulation systems to treat fecal incontinence. Japanese J Gstro Hepato 2020; 5: 1–5.
Google Scholar40. Peters, KM, Macdiarmid, SA, Wooldridge, LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 182: 1055–1061.
Google Scholar | Crossref | Medline | ISI41. Finazzi-Agrò, E, Petta, F, Sciobica, F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol 2010; 184: 2001–2006.
Google Scholar | Crossref | Medline | ISI42. de Wall, LL, Heesakkers, JP. Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. Res Rep Urol 2017; 9: 145–157.
Google Scholar | Medline43. Groen, J, Amiel, C, Bosch, JR. Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: results of a pilot study with a novel minimally invasive implantable mini-stimulator. Neurourol Urodyn 2005; 24: 226–230.
Google Scholar | Crossref | Medline44. Vollstedt, A, Gilleran, J. Update on implantable PTNS devices. Curr Urol Rep 2020; 21: 28.
Google Scholar | Crossref | Medline45. Peters, KM, Carrico, DJ, Perez-Marrero, RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010; 183: 1438–1443.
Google Scholar | Crossref | Medline | ISI46. Peters, KM, Carrico, DJ, Wooldridge, LS, et al. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol 2013; 189: 2194–2201.
Google Scholar | Crossref | Medline | ISI47. Marinkovic, SP . New technologies in the management of overactive bladder: current research and future prospects. Ther Adv Urol 2019; 11: 1756287219844669.
Google Scholar | SAGE Journals | ISI48. Farag, FF, Martens, FM, Rijkhoff, NJ, et al. Dorsal genital nerve stimulation in patients with detrusor overactivity: a systematic review. Curr Urol Rep 2012; 13: 385–388.
Google Scholar |

留言 (0)

沒有登入
gif